Bimal Patel, DO
Interventional Pain Medicine · Metuchen, NJNPI 1174899116
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,252 of the $11,461 with a category attached, or 72.0%. It is spread thinly across 40 manufacturers, the largest accounting for just 20.1%. Reporting peaked in 2019 at $5,689 and has fallen 87.5% since, to $709 in 2025.
Across 322 payments — averaging $35.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertiflex, Inc.$2K
- Nevro Corp.$2K
- Abbott$1K
- Saluda Medical Americas, Inc.$904
- Vertos Medical, Inc.$838
- Boston Scientific$644
- plus $4K from 34 others
What the payments were for
- Travel & lodging$3,20928%
- Food & beverage$8,25272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,461 in reported general payments places this provider in the 80th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 17 | $3,352 |
| Gabapentin | 97 | $1,234 |
| Pregabalin | 60 | $1,140 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 43 | $869 |
| Cyclobenzaprine Hcl | 20 | $538 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $238 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 22 | $233 |
| Tramadol Hcl | 47 | $217 |
| Methylprednisolone | 22 | $214 |
| Tizanidine Hcl | 35 | $204 |
| Meloxicam | 17 | $96 |
| Diazepam | 26 | $21 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Metuchen
- Karim IssaMetuchen$4K
- Youssef JosephsonWest Deptford$496K
- Ali ValimahomedHolmdel$415K
- Saurabh DangEdgewater$157K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Steve AydinFranklin Lakes$22K
- Kieran SlevinHainesport$21K
- John CoccaroToms River$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.